VU 0134992 是第一个亚型偏好的，口服有效的和选择性的内向整流钾通道Kir4.1阻滞剂，IC50为 0.97 μM。在 -120 mV 时，VU0134992对同分 Kir4.1 比 Kir4.1/5.1 共分通道 (IC50=9 μM) 高出 9 倍的选择性。

VU0134992 is an Kir4.1 blocker with an IC50 value of 0.97 μM

VU0134992 inhibits Kir4.1 with an IC50 value of 0.97 μM and is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50 = 9 μM) at -120 mV.?In thallium (Tl+) flux assays, VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2;?is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1;?and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2.

VU0134992 displayed a large free unbound fraction (fu) in rat plasma (fu = 0.213).?Consistent with the known role of Kir4.1 in renal function, oral dosing of VU0134992 led to a dose-dependent diuresis, natriuresis, and kaliuresis in rats.

755002-90-5

C20H31BrN2O2

411.384

VU 0134992;VU0134992

DMSO:60 mg/ml (145.85 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years